One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along ...